AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Sepsis Treatment Inactivates Endotoxins Using Molecules Derived From Chitosan Derivative

Summary

Purdue University researchers have developed a novel treatment for septicemia involving molecules derived from chitosan. Chitosan is a linear carbohydrate with many commercial and biomedical uses. This treatment inactivates endotoxins, which are toxins associated with certain types of bacteria and stimulates cytokine release (part of the body's inflammatory response that causes swelling and high fever). This new chitosan shows many advantages over current IV treatments for septicemia. This technology can be used to filter endotoxins out of plasmid DNA samples and filter bacteria from water, making contaminated water samples safe to drink.

Technology Benefits

Stronger affinity for inactivating endotoxinsExcellent biocompatibility upon injection Lower potential to cause hemolysis, complement activation, and inflammatory responsesCan filter endotoxins out of plasmid DNA samples and remove bacteria from water

Technology Application

Medical/HealthSepsis treatmentContaminant removal from drinking water

Detailed Technology Description

Yoon YeoYeo LabPurdue Industrial and Physical Pharmacy

Countries

United States

Application No.

None

Country/Region

USA

For more information, please click Here